Skip to content

Study on reduction of skin autofluorescence (SAF) by various supplements

Self-controlled, open-label, pre/post comparison study of functional supplements to characterize changes in SAF and study on population with reduced SAF - Research on individuals showing reduction of SAF by taking supplements

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000049951
Enrollment
180
Registered
2023-04-01
Start date
2023-03-31
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced glycation end-products

Interventions

Hydrogen-releasing supplements for 20 weeks or Reduced form of CoQ10 for 20 weeks or Foods containing Salacia ingredients for 20 weeks or Foods containing mulberry leaf ingredients for 20 weeks or

Sponsors

Okayama University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Those who have at least 1 S.D. above the mean SAF for the subject's age at the time of screening prior to obtaining consent 2. Those who are 20 years-old or older at the time of obtaining consent 3. Those who have given their free written consent after receiving sufficient explanation for participation in this research

Exclusion criteria

Exclusion criteria: 1. Those who are below the SAF average for the subject's age, or those who are above the average but below 1 S.D. at the time of screening prior to obtaining consent 2. Those who have a SAF value variation of more than plus/minus 0.2 a.u. from the SAF value at screening during the previous observation period 3. Those who are 70 years-old or older, BMI 30 or higher, and current smoker at the time of consent 4. Those who suspected alcohol or caffeine addiction 5. Those who with extremely irregular lifestyle 6. Those who have history of cardiovascular disease (males only), diabetes mellitus, or renal failure (on dialysis) 7. Patients with severe renal disease (more than BUN 25 mg/dL or serum creatinine 2.0 mg/dL) 8. Patients with severe liver disease (more than AST (GOT) or ALT (GPT) 100 U) 9. Pregnant or possibly pregnant or lactating women 10. Those who are drug addiction 11. Individuals who are deemed inappropriate as research participants by the principal investigator

Design outcomes

Primary

MeasureTime frame
Comparison of the difference between the mean SAF at the end of the last week (week 20) of supplementation and the mean SAF during the previous observation period (1-2 weeks) in individual subjects

Countries

Japan

Contacts

Public ContactNoritaka Ariyoshi

Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences

pmaphs.ou@gmail.com086-235-6619

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026